Literature DB >> 9366929

Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium.

H Berg1, J Roed, J Viby-Mogensen, C R Mortensen, J Engbaek, L T Skovgaard, J J Krintel.   

Abstract

BACKGROUND: After anaesthesia involving pancuronium a high incidence of both residual neuromuscular block and postoperative pulmonary complications (POPC) has been reported. The aim of this study was to compare the incidence of POPC following the use of pancuronium, atracurium, and vecuronium, and to examine the effect of residual neuromuscular block on the incidence of POPC.
METHODS: A total of 691 adult patients undergoing abdominal, gynaecological, or orthopaedic surgery under general anaesthesia were randomised to receive either pancuronium, atracurium, or vecuronium. Perioperatively, the response to train-of-four (TOF) nerve stimulation was evaluated manually. Postoperatively, the TOF ratios were measured mechanomyographically, and through a 6-day follow-up the patients were examined for pulmonary complications.
RESULTS: The incidence of residual block, defined as a TOF ratio < 0.7, was significantly higher in the pancuronium group (59/226: 26%) than in the atracurium/vecuronium groups (24/450: 5.3%). In the pancuronium group, significantly more patients with residual block developed POPC (10/59: 16.9%) as compared to patients without residual block (8/167: 4.8%). In the atracurium/vecuronium groups, the incidence of POPC was not significantly different in patients with (1/24: 4.2%) or without (23/426: 5.4%) residual block. Multiple regression analysis indicated that abdominal surgery, age, long-lasting surgery, and a TOF ratio < 0.7 following the use of pancuronium were potential risk factors for the development of POPC.
CONCLUSION: Postoperative residual block caused by pancuronium is a significant risk factor for development of POPC.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9366929     DOI: 10.1111/j.1399-6576.1997.tb04851.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  92 in total

1.  Efficacy of different doses of sugammadex after continuous infusion of rocuronium.

Authors:  Diego Soto Mesa; Mounir Fayad Fayad; Laura Pérez Arviza; Verónica Del Valle Ruiz; Fernando Cosío Carreño; Luis Arguelles Tamargo; Manuel Amorín Díaz; Sergio Fernández-Pello Montes
Journal:  World J Clin Cases       Date:  2015-04-16       Impact factor: 1.337

Review 2.  [Residual neuromuscular blockades. Clinical consequences, frequency and avoidance strategies].

Authors:  T Fuchs-Buder; M Eikermann
Journal:  Anaesthesist       Date:  2006-01       Impact factor: 1.041

Review 3.  [Neuromuscular blockades. Agents, monitoring and antagonism].

Authors:  J-U Schreiber; T Fuchs-Buder
Journal:  Anaesthesist       Date:  2006-11       Impact factor: 1.041

Review 4.  Newer neuromuscular blocking agents: how do they compare with established agents?

Authors:  H J Sparr; T M Beaufort; T Fuchs-Buder
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 5.  [Minimizing perioperative risk - an interdisciplinary effort].

Authors:  Matthias Bock; Christian J Wiedermann
Journal:  Wien Med Wochenschr       Date:  2008

6.  Computerized recording of neuromuscular monitoring and the risk of residual paralysis at the time of extubation.

Authors:  Cyrus Motamed; Jean-Louis Bourgain
Journal:  J Clin Monit Comput       Date:  2008-08-07       Impact factor: 2.502

Review 7.  ERCP: the unresolved question of endotracheal intubation.

Authors:  Basavana Goudra; Preet Mohinder Singh
Journal:  Dig Dis Sci       Date:  2013-11-13       Impact factor: 3.199

8.  Is anesthesia dangerous?

Authors:  André Gottschalk; Hugo Van Aken; Michael Zenz; Thomas Standl
Journal:  Dtsch Arztebl Int       Date:  2011-07-08       Impact factor: 5.594

Review 9.  Selecting neuromuscular-blocking drugs for elderly patients.

Authors:  Tristan M Cope; Jennifer M Hunter
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

10.  Novel drug development for neuromuscular blockade.

Authors:  Amit Prabhakar; Alan D Kaye; Melville Q Wyche; Orlando J Salinas; Kenneth Mancuso; Richard D Urman
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2016 Jul-Sep
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.